21:12 , Jan 23, 2018 |  BC Innovations  |  Distillery Therapeutics

Other; hematology

INDICATION: Poisoning; hematology Mouse studies suggest GnRH/LHRH receptor antagonists could help treat radiation poisoning and chemotherapy-induced myelosuppression. In mice exposed to lethal whole-body radiation, the GnRH/LHRH receptor antagonist Firmagon degarelix increased counts of red blood cells,...
07:00 , Jun 9, 1997 |  BioCentury  |  Strategy

Praecis deal a lesson in matchmaking

Noteworthy Praecis Pharmaceuticals Inc.'s $78 million deal with Synthelabo is a reminder that biotech companies still command leverage when they can bring a partner an advanced product that fits a particular need. The agreement, announced last...
08:00 , Jan 10, 1994 |  BC Week In Review  |  Company News

Atrix deal

Syntex is studying LH-RH antagonists to treat prostatic cancer, uterine fibroids, endometriosis and related diseases. The agreement comes at the end of a period of preliminary research to determine whether Syntex's ganirelix LH-RH antagonist is...